TCL Archive Rescission Cuts $5-6 Mil. From NCI FY94 Appropriations , Affects Intramural Program March 11, 1994
TCL Archive Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent January 27, 2012
TCL Archive FDA Committee Okays Leuprolide NDA, But Recommends Against Mitoxantrne, Epirubicin April 5, 1985
TCL Archive Also von Eschenbach Role in Industry Program Raises New Concerns of Conflict of Interest. November 22, 2006
